<DOC>
	<DOCNO>NCT01568788</DOCNO>
	<brief_summary>Phase III clinical trial carry Jintan city , Jiangsu Province , China May , 2006 . Trial result show vaccine prove safety immunogenicity . Influenza vaccine Hualanbio obtain production permission marketing authorization May , 2008 . In order investigate safety immunogenicity vaccine market , The clinical observation plan conduct Mianyang city ( Yanting County ) , Sichuan Province , China .</brief_summary>
	<brief_title>Post-marketing Clinical Observation Inactivated Influenza Split Vaccine</brief_title>
	<detailed_description>Dosage administration route clinical trial : Subjects age 3 year older vaccinate follow single 0.5ml dose immunization regime . The preferred site injection skin near outboard deltoid muscle upper arm . The administration route sanitization 75 % alcohol , intramuscularly inject test vaccine control vaccines skin slightly dry subject comply inclusion requirement . Safety indicator : - Post-vaccination local systemic adverse reaction level , together solicit adverse reaction within 30 minute ; - Post-vaccination local systemic adverse reaction level , together solicit adverse reaction 6 hour 29th day ; - Summarize adverse events/severe adverse event incidence level inclusion subject completion clinical trial . Immunogenicity indicator : Evaluate Post-vaccination immunogenicity test control influenza vaccine person age 3 year old HI antibody level Day 28 . Take 1:10 serum dilution minimum dilutability . The seroconversion trial define post-vaccination HI antibody titer ≥ 1:40 HI antibody &lt; 1:10 vaccination post-vaccination HI antibody titer quadruply increase HI antibody ≥ 1:10 vaccination . The Immunogenicity criterion set clinical trial seroconversion shall ＞ 40 % 14 day vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female age 3 old , volunteer guardian able understand sign inform consent ; Healthy male female inquire illness history , physical examination clinical judgment complies vaccination product ; Be able comply requirement clinical trial protocol ; Have history vaccination within past 6 month vaccination product within late 1 week ; Axillary temperature ＜37.1℃ . Subject allergic egg component vaccine , history allergy ; Fever , acute disease acute onset chronic disease influenza ; GuillainBarre Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Respiratory Tract Infections ; Orthomyxoviridae Infections</keyword>
</DOC>